Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Major Shareholder Purchases $166,214.08 in Stock

Aclaris Therapeutics, Inc. (NASDAQ:ACRS – Get Free Report) major shareholder Braden Michael Leonard purchased 143,288 shares of the business’s stock in a transaction on Wednesday, July 3rd. The stock was purchased at an average cost of $1.16 per share, for a total transaction of $166,214.08. Following the acquisition, the insider now owns 13,324,952 shares in […]

Leave a Reply

Your email address will not be published.

Previous post Analysts Set JFrog Ltd. (NASDAQ:FROG) Price Target at $43.93
Next post ALX Oncology Holdings Inc. (NASDAQ:ALXO) Receives Consensus Recommendation of “Moderate Buy” from Brokerages